NECTAR IIINCT05363761
Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
At risk: Primary completion moved at least 2 years 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 2025 to May 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 70 words
- Enrollment closed, study ongoing
- Study completion moved earlier from Jan 2029 to Dec 2027
- Secondary endpoints: details revised at 2 of 2 entries
- Site details revised at 3 of 3 sites
Notable Lead sponsor: [Redacted] to Neurotronic, Inc.v2 Show 6 more changesShow less
- Trial status: Withheld to Recruiting
- Primary completion date: Jan 2025
- Study completion date: Jan 2029
- Start date: Apr 19, 2022
- Study title revised
- Collaborators expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of serious device- and procedure-related complications at 30 days post procedure.
Timeframe: 30 Days
Device success
Timeframe: During the procedure
Secondary (2)
Glycemic Control:
Hypertension Control:
Arms and interventions
Ablation TreatmentExperimental
Neurotronic Infusion Catheter Treatment
Combination products: Neurotronic Infusion Catheter
Sites
3 sites in 2 countries
Panama 2, Paraguay 1